Retinal Vein Occlusion Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Retinal Vein Occlusion is a blockage in one of the veins returning blood flow from the retina. Its predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol, and age.

The Retinal Vein Occlusion pipeline market research report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects.

Retinal Vein Occlusion Pipeline Products Market Segmentation by Targets

The key targets in the Retinal Vein Occlusion pipeline products market are Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, Phospholipase A2, Placenta Growth Factor, Protein Kinase C, Angiopoietin 2, Vascular Endothelial Growth Factor Receptor 2, Glucocorticoid Receptor, Vascular Endothelial Growth Factor Receptor 1, and Angiopoietin 1 Receptor, among others. Vascular Endothelial Growth Factor A has the highest number of products in the Retinal Vein Occlusion pipeline products market.

Retinal Vein Occlusion Pipeline Products Market Analysis by Targets

For more target insights into the Retinal Vein Occlusion pipeline products market, download a free report sample

Retinal Vein Occlusion Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Retinal Vein Occlusion pipeline products market are Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Phospholipase A2 Inhibitor, Placenta Growth Factor Inhibitor, Protein Kinase C Inhibitor, Angiopoietin 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Angiopoietin 1 Receptor Agonist, and Calpain 1 Catalytic Subunit Inhibitor, among others. Vascular Endothelial Growth Factor A Inhibitor leads the Retinal Vein Occlusion pipeline products market in terms of MoA.

Retinal Vein Occlusion Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Retinal Vein Occlusion pipeline products market, download a free report sample

Retinal Vein Occlusion Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Retinal Vein Occlusion pipeline products market are intravitreal, intravenous, ophthalmic, intraocular, parenteral, and topical. Intravitreal leads the Retinal Vein Occlusion pipeline products market in terms of RoA.

Retinal Vein Occlusion Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Retinal Vein Occlusion pipeline products market, download a free report sample

Retinal Vein Occlusion Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Retinal Vein Occlusion pipeline products market are small molecule, monoclonal antibody, fusion protein, synthetic peptide, recombinant protein, gene therapy, aptamer, monoclonal antibody conjugated, and protein. Small molecule leads the Retinal Vein Occlusion pipeline products market in terms of molecule type.\

Retinal Vein Occlusion Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the Retinal Vein Occlusion pipeline products market, download a free report sample

Retinal Vein Occlusion Pipeline Products Market - Competitive Landscape

Some of the leading companies in the Retinal Vein Occlusion pipeline products market are ANBITION Srl, Annexin Pharmaceuticals AB, Ocular Therapeutix Inc, Avirmax Inc, Kala Pharmaceuticals Inc, Luye Pharma Group Ltd, 3SBio Inc, Allgenesis Biotherapeutics Inc, and AsclepiX Therapeutics Inc. ANBITION Srl is the leading company in the Retinal Vein Occlusion pipeline products market.

Retinal Vein Occlusion Pipeline Products Market Analysis by Companies

To know more about the leading players in the Retinal Vein Occlusion pipeline products market, download a free report sample

Retinal Vein Occlusion Pipeline Products Market Report Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.